Donor-specific antibodies are associated with antibody-mediated rejection, acute cellular rejection, bronchiolitis obliterans syndrome, and cystic fibrosis after lung transplantation

被引:137
作者
Lobo, Leonard J. [1 ]
Aris, Robert M. [1 ]
Schmitz, John
Neuringer, Isabel. P. [2 ]
机构
[1] Univ N Carolina, Div Pulm & Crit Care Med, Chapel Hill, NC 27599 USA
[2] Massachusetts Gen Hosp, Pulm & Crit Care Unit, Boston, MA 02114 USA
关键词
lung transplant; donor-specific antibodies; antibody-mediated rejection; cystic fibrosis; lung allograft dysfunction; HLA ANTIBODIES; C4D DEPOSITION; ALLOGRAFT; SENSITIZATION; LYMPHOCYTES; RECIPIENTS; RELEVANCE; INFECTION; DIAGNOSIS; UPDATE;
D O I
10.1016/j.healun.2012.10.007
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BACKGROUND: Lung transplantation is limited by chronic lung allograft dysfunction. Acute cellular rejection (ACR) is a risk factor for allograft dysfunction; however, the role of antibody-mediated rejection (AMR) is not well characterized. METHODS: This was a retrospective review from 2007 to 2011 of lung transplant recipients with human leukocyte antigen (HLA) antibody testing using Luminex (Luininex Corp, Austin, TX) single-antigen beads. Statistics included Fisher's exact test for significance. RESULTS: Donor-specific antibodies (DSA) developed in 13 of 44 patients. Of the 13 with DSA, 12 had cystic fibrosis compared with 18 of 31 in the non-DSA group (p = 0.035). Of those with DSAs, 23.1% occurred within the first year, and 69.2% occurred between 1 and 3 years. Twelve of 13 DSA patients had anti-HLA DQ specificity compared with 2 of 31 non-DSA patients (p = 0.0007). AMR developed in 10 of the 13 DSA patients compared with 1 of 31 non-DSA patients (p = 0.0001). The DSA group experienced 2.6 episodes/patient of cellular rejection vs 1.7 episodes/patient in the non-DSA group (p = 0.059). Bronchiolitis obliterans syndrome developed in 11 of 13 in the DSA group vs 10 of 31 in the non-DSA group (p = 0.0024). In the DSA group, 11.5% HLAs matched compared with 20.4% in the non-DSA group (p = 0.093). AMR developed in 11 of 22 patients in the non-DSA HLA group compared with 0 of 22 in the group without non-DSA HLA antibodies (p = 0.002). Survival at 1 and 3 years was 92% and 36% in the DSA group, respectively, and 97% and 65% in the non-DSA group. CONCLUSIONS: DSAs and non-DSAs occur frequently after lung transplantation. DSAs are prevalent in the cystic fibrosis population and are associated with AMR, bronchiolitis obliterans syndrome, and possibly, ACR. J Heart Lung Transplant 2013;32:70-77 (C) 2013 International Society for Heart and Lung Transplantation. All rights reserved.
引用
收藏
页码:70 / 77
页数:8
相关论文
共 50 条
[1]   Utility of peritransplant and rescue intravenous immunoglobulin and extracorporeal immunoadsorption in lung transplant recipients sensitized to HLA antigens [J].
Appel, JZ ;
Hartwig, MG ;
Davis, RD ;
Reinsmoen, NL .
HUMAN IMMUNOLOGY, 2005, 66 (04) :378-386
[2]   HLA class II polymorphism in cystic fibrosis - A possible modifier of pulmonary phenotype [J].
Aron, Y ;
Polla, BS ;
Bienvenu, T ;
Dall'Ava, J ;
Dusser, D ;
Hubert, D .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 1999, 159 (05) :1464-1468
[3]   Pseudomonas aeruginosa colonization of the allograft after lung transplantation and the risk of bronchiolitis obliterans syndrome [J].
Botha, Phil ;
Archer, Lynda ;
Anderson, Rachel L. ;
Lordan, Jim ;
Dark, John H. ;
Corris, Paul A. ;
Gould, Kate ;
Fisher, Andrew J. .
TRANSPLANTATION, 2008, 85 (05) :771-774
[4]   Relative impact of human leukocyte antigen mismatching and graft ischemic the after lung transplantation [J].
Brugiere, Olivier ;
Thabut, Gabriel ;
Suberbielle, Caroline ;
Reynaud-Gaubert, Martine ;
Thomas, Pascal ;
Pison, Christophe ;
Saint Raymond, Christel ;
Mornex, Jean-Francois ;
Bertocchi, Michele ;
Dromer, Claire ;
Velly, Jean-Francois ;
Stern, Marc ;
Philippe, Bruno ;
Dauriat, Gaelle ;
Biondi, Giuseppina ;
Castier, Yves ;
Fournier, Michel .
JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2008, 27 (06) :628-634
[5]   Pathogen and autoantigen homologous regions within the cystic fibrosis transmembrane conductance regulator (CFTR) protein suggest an autoimmune treatable component of cystic fibrosis [J].
Carter, Chris J. .
FEMS IMMUNOLOGY AND MEDICAL MICROBIOLOGY, 2011, 62 (02) :197-214
[6]   Current methodologies for detecting sensitization to HLA antigens [J].
Cecka, J. Michael .
CURRENT OPINION IN ORGAN TRANSPLANTATION, 2011, 16 (04) :398-403
[7]   Human leukocyte antigen mismatches predispose to the severity of bronchiolitis obliterans syndrome after lung transplantation [J].
Chalermskulrat, W ;
Neuringer, IP ;
Schmitz, JL ;
Catellier, DJ ;
Gurka, MJ ;
Randell, SH ;
Aris, RM .
CHEST, 2003, 123 (06) :1825-1831
[8]   The Registry of the International Society for Heart and Lung Transplantation: Twenty-seventh official adult lung and heart-lung transplant report-2010 [J].
Christie, Jason D. ;
Edwards, Leah B. ;
Kucheryavaya, Anna Y. ;
Aurora, Paul ;
Dobbels, Fabienne ;
Kirk, Richard ;
Rahmel, Axel O. ;
Stehlik, Josef ;
Hertz, Marshall I. .
JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2010, 29 (10) :1104-1118
[9]   Update on gene modifiers in cystic fibrosis [J].
Collaco, Joseph M. ;
Cutting, Garry R. .
CURRENT OPINION IN PULMONARY MEDICINE, 2008, 14 (06) :559-566
[10]   Non-organ-specific and anti-endothelial antibodies in relation to CMV infection and acute rejection in renal transplant recipients [J].
Costa, Cristina ;
Touscoz, Giovanni Antonio ;
Bergallo, Massimiliano ;
Terlizzi, Maria Elena ;
Astegiano, Sara ;
Sidoti, Francesca ;
Sinesi, Franca ;
Segoloni, Giuseppe P. ;
Cavallo, Rossana .
CLINICAL TRANSPLANTATION, 2010, 24 (04) :488-492